Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

(2019) Boris Julg et al.   Lancet HIV

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Trevor A Crowell et al.   Lancet HIV

Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders

(2018) Silvia Ratto-Kim et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

(2018) Lindsey R Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

(2018) Dan H Barouch et al.   LANCET

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

(2018) Donn J. Colby et al.   NATURE MEDICINE

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

(2018) Kathryn E. Stephenson et al.   PLoS One

Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia

(2018) David Chang et al.   Journal of the International AIDS Society

Delayed differentiation of potent effector CD8 + T cells reducing viremia and reservoir seeding in acute HIV infection

(2017) Hiroshi Takata et al.   Science Translational Medicine

Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa

(2016) Damalie Nakanjako et al.   AIDS

Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology

(2016) Mark S. de Souza et al.   CLINICAL INFECTIOUS DISEASES

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

(2016) Erica N. Borducchi et al.   NATURE

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

International AIDS Society global scientific strategy: towards an HIV cure 2016

(2016) Steven G Deeks et al.   NATURE MEDICINE

Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection

(2015) Mark S. De Souza et al.   AIDS

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

(2015) Beatriz Mothe et al.   Journal of Translational Medicine

COMPASS identifies T-cell subsets correlated with clinical outcomes

(2015) Lin Lin et al.   NATURE BIOTECHNOLOGY

Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies

(2014) C. Vandergeeten et al.   JOURNAL OF VIROLOGY

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

(2013) Asier Sáez-Cirión et al.   PLoS Pathogens

HLA/KIR Restraint of HIV: Surviving the Fittest

(2011) Arman A. Bashirova et al.   Annual Review of Immunology

Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial

(2011) Jonathan Z. Li et al.   JOURNAL OF INFECTIOUS DISEASES

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

(2010) Margaret E. Ackerman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein

(2010) Robert T. Schooley et al.   JOURNAL OF INFECTIOUS DISEASES

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

(2010) Dan H Barouch et al.   NATURE MEDICINE

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories

(2009) Sally Land et al.   JOURNAL OF VIROLOGICAL METHODS

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA